Kyle Zingaro

Head of Gene Therapy Drug Substance Process Sciences at UCB

Kyle has 10+ years of experience leading technical and operational teams in preclinical through post-commercial development of biologics. Kyle is the UCB Head of Gene Therapy Drug Substance Process Sciences where he is accountable for leading the internal and external development of the manufacturing processes for UCBs gene therapy portfolio.

Prior to joining UCB, Kyle was Head of Process Sciences at Thermo Fisher Scientific Viral Vector Services (formerly Brammer Bio) where he was responsible for leading commercial stage tech transfer and late-phase process development of Thermo Fisher's cell & gene therapy offerings. He holds a B.S. in biochemistry from Virginia Tech and a Ph.D. in chemical engineering from University of Delaware